Adenosine A3 receptors areG protein-coupled receptors that couple to Gi/Gq and are involved in a variety of intracellular signaling pathways and physiological functions. It mediates a sustained cardioprotective function duringcardiac ischemia, it is involved in the inhibition ofneutrophildegranulation in neutrophil-mediated tissue injury, it has been implicated in both neuroprotective and neurodegenerative effects, and it may also mediate both cell proliferation and cell death[citation needed].Recent publications demonstrate that adenosine A3 receptor antagonists (SSR161421) could have therapeutic potential in bronchial asthma (17,18).
^Bevan N, Butchers PR, Cousins R, Coates J, Edgar EV, Morrison V, et al. (June 2007). "Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor antagonist activity".European Journal of Pharmacology.564 (1–3):219–225.doi:10.1016/j.ejphar.2007.01.094.PMID17382926.
^Priego EM, Pérez-Pérez MJ, von Frijtag Drabbe Kuenzel JK, de Vries H, Ijzerman AP, Camarasa MJ, Martín-Santamaría S (January 2008). "Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding".ChemMedChem.3 (1):111–119.doi:10.1002/cmdc.200700173.hdl:10261/82277.PMID18000937.S2CID7128294.
^Courtney L. Fisher, Matteo Pavan, Veronica Salmaso, Robert F. Keyes, Tina C. Wan, Balaram Pradhan, Zhan-Guo Gao, Brian C. Smith, Kenneth A. Jacobson and John A. Auchampach. [<https://doi.org/10.1124/molpharm.123.000784> "Extrahelical binding site for a 1H-imidazo[4,5-c]quinolin-4-amine A3 adenosine receptor positive allosteric modulator on helix 8 and distal portions of transmembrane domains 1 and 7"]
^Mikus EG, Szeredi J, Boer K, Tímári G, Finet M, Aranyi P, Galzin AM (January 2013). "Evaluation of SSR161421, a novel orally active adenosine A3 receptor antagonist on pharmacology models".European Journal of Pharmacology.699 (1–3):172–179.doi:10.1016/j.ejphar.2012.11.049.PMID23219796.
^Mikus EG, Boér K, Timári G, Urbán-Szabó K, Kapui Z, Szeredi J, et al. (January 2013). "Interaction of SSR161421, a novel specific adenosine A(3) receptor antagonist with adenosine A(3) receptor agonists both in vitro and in vivo".European Journal of Pharmacology.699 (1–3):62–66.doi:10.1016/j.ejphar.2012.11.046.PMID23219789.
Atkinson MR, Townsend-Nicholson A, Nicholl JK, Sutherland GR, Schofield PR (September 1997). "Cloning, characterisation and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene".Neuroscience Research.29 (1):73–79.doi:10.1016/S0168-0102(97)00073-4.PMID9293494.S2CID36060683.
Palmer TM, Harris CA, Coote J, Stiles GL (October 1997). "Induction of multiple effects on adenylyl cyclase regulation by chronic activation of the human A3 adenosine receptor".Molecular Pharmacology.52 (4):632–640.doi:10.1124/mol.52.4.632.PMID9380026.S2CID2170191.
Broussas M, Cornillet-Lefèbvre P, Potron G, Nguyên P (July 2002). "Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: involvement of the A3 adenosine receptor".Thrombosis and Haemostasis.88 (1):123–130.doi:10.1055/s-0037-1613164.PMID12152652.S2CID3118696.
"Adenosine Receptors: A3".IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived fromthe original on 2020-11-30. Retrieved2008-11-25.
